- Oops!Something went wrong.Please try again later.
EQS Group-News: Achiko AG / Key word(s): Conference
Achiko AG: Invitation to the H1 2021 Financial Results Presentation
Zurich, 23 September 2021
The event will be conducted as a virtual Zoom Meeting, led by Steven Goh, CEO of Achiko AG, and Robert Rieder, CFO of Achiko AG. Please note that the presentation will be in English.
Date: Monday, September 27, 2021 at 08.00 a.m. (CEST)
Participants are advised to log on to the conference and register their details 10 minutes prior to the conference call.
The company's H1 2021 financial results will be released on Monday, September 27, 2021 at 06:30 a.m. (CEST) and will be made available on our website at https://www.achiko.com/financials.
A replay of the presentation and the Q&A session will be available shortly after the conference call and can be accessed any time on our website at https://www.achiko.com/financials.
AptameX comprises of DNA aptamer-based technology that is cost-effective, chemically synthesised and widely applicable to the evolving diagnostic field of healthcare. Together with the digital mobile health app Teman Sehat, Achiko is developing potential technologies that seek to deliver rapid, affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications. The AptameX technology is licensed from Regenacellx.sl and Achiko has exclusive commercialisation rights.
Headquartered in Zurich, Achiko has offices in Hong Kong, Jakarta, Seoul and Singapore.
Further information can be found at www.achiko.com.
Switzerland & Global
U.S. & Global
End of Media Release
SIX Swiss Exchange
EQS News ID:
End of News
EQS Group News Service